# Anticoagulation Length in Cancer Associated Thrombosis

> **NCT01817257** · PHASE2 · TERMINATED · sponsor: **Cardiff University** · enrollment: 2 (actual)

## Conditions studied

- Cancer
- Thrombosis
- Venous Thromboembolism
- Deep Vein Thrombosis
- Pulmonary Embolus

## Interventions

- **DRUG:** Low Molecular Weight Heparin (LMWH)

## Key facts

- **NCT ID:** NCT01817257
- **Lead sponsor:** Cardiff University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Early findings showed trial was not feasible
- **Last updated:** 2018-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817257, "Anticoagulation Length in Cancer Associated Thrombosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01817257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*